2021
DOI: 10.2196/preprints.31143
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Prediction of the financial risk of Special Treatment of a Listed Pharmaceutical Company in China: A Principal Component Analysis (Preprint)

Abstract: BACKGROUND The listed pharmaceutical industry of China is growing swiftly by about 10% interest per year. However, risk always keeps pace with improvements. In China, listed companies with significant financial distress or irregularities will be assigned a special treatment (ST) label indicating a risk warning. Recently, eight listed pharmaceutical companies with a ST sign are surviving with but present serious investment risks. … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 13 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?